Antifungal Prophylaxis with Posaconazole Delayed-Release Tablet and Oral Suspension in a Real-Life Setting: Plasma Levels, Efficacy, and Tolerability

We continuously determined posaconazole plasma concentrations (PPCs) in 61 patients with hematological malignancies receiving posaconazole (PCZ) delayed-release tablets (DRT; 48 patients; median duration of intake, 92 days) and PCZ oral solution (OS; 13 patients; median duration of intake, 124 days)...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Antimicrob Agents Chemother
Auteurs principaux: Lenczuk, David, Zinke-Cerwenka, Wilma, Greinix, Hildegard, Wölfler, Albert, Prattes, Jürgen, Zollner-Schwetz, Ines, Valentin, Thomas, Lin, Timothy C., Meinitzer, Andreas, Hoenigl, Martin, Krause, Robert
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2018
Sujets:
Clinical Therapeutics
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5971564/
https://ncbi.nlm.nih.gov/pubmed/29581116
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02655-17
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires